Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taussig

Showing results (541-550 of 561) with videos related to

Pageof 57
Sort By:
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
The New England Journal of Medicine|November 25, 2011
Daily or intermittent budesonide in preschool children with recurrent wheezingRobert S Zeiger, David Mauger, Leonard B Bacharier, et al.
Blood|August 19, 2024
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS studyTeena Bhatla, Laura E Hogan, David T Teachey, et al.
Clinical Chemistry and Laboratory Medicine|June 17, 2009
Approaching clinical proteomics: current state and future fields of application in fluid proteomicsRolf Apweiler, Charalampos Aslanidis, Thomas Deufel, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 10, 2009
Approaching clinical proteomics: current state and future fields of application in cellular proteomicsRolf Apweiler, Charalampos Aslanidis, Thomas Deufel, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Neurophysiologie Clinique = Clinical Neurophysiology|December 27, 2017
French guidelines on stereoelectroencephalography (SEEG)Jean Isnard, Delphine Taussig, Fabrice Bartolomei, et al.
New Biotechnology|October 19, 2010
"4D Biology for health and disease" workshop reportJan-Pieter Abrahams, Rolf Apweiler, Rudi Balling, et al.
Blood Advances|December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AMLCarlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Blood|January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AMLRichard Dillon, Robert Hills, Sylvie Freeman, et al.
Pageof 57

Showing results (541-550 of 561) with videos related to

Sort By:
Pageof 57
Blood Advances|February 1, 2023
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AMLStéphane de Botton, Pierre Fenaux, Karen Yee, et al.
The New England Journal of Medicine|November 25, 2011
Daily or intermittent budesonide in preschool children with recurrent wheezingRobert S Zeiger, David Mauger, Leonard B Bacharier, et al.
Blood|August 19, 2024
Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS studyTeena Bhatla, Laura E Hogan, David T Teachey, et al.
Clinical Chemistry and Laboratory Medicine|June 17, 2009
Approaching clinical proteomics: current state and future fields of application in fluid proteomicsRolf Apweiler, Charalampos Aslanidis, Thomas Deufel, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|September 10, 2009
Approaching clinical proteomics: current state and future fields of application in cellular proteomicsRolf Apweiler, Charalampos Aslanidis, Thomas Deufel, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Neurophysiologie Clinique = Clinical Neurophysiology|December 27, 2017
French guidelines on stereoelectroencephalography (SEEG)Jean Isnard, Delphine Taussig, Fabrice Bartolomei, et al.
New Biotechnology|October 19, 2010
"4D Biology for health and disease" workshop reportJan-Pieter Abrahams, Rolf Apweiler, Rudi Balling, et al.
Blood Advances|December 1, 2023
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AMLCarlos Jimenez-Chillon, Jad Othman, David Taussig, et al.
Blood|January 15, 2020
Molecular MRD status and outcome after transplantation in NPM1-mutated AMLRichard Dillon, Robert Hills, Sylvie Freeman, et al.
Pageof 57